1-bromo-3'-propoxyacetophenone | 121704-78-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-bromo-3'-propoxyacetophenone
• 英文别名: 2-bromo-1-(3-propoxyphenyl)ethanone；2-bromo-3'-propoxyacetophenone
• CAS: 121704-78-7
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: FASDSPLVBVJWOM-UHFFFAOYSA-N

物化性质

• 沸点：
  309.7±17.0 °C(Predicted)
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-bromo-3'-propoxyacetophenone 在 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 39.08h， 生成 1-(benzo[d][1,3]dioxol-5-yl)-N-(4-phenyl-5-(3-propoxybenzoyl)thiazol-2 yl)cyclopropanecarboxamide
  参考文献：
  名称：

  Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays

  摘要：

  Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. It is caused by different mutations in the cystic fibrosis transmembrane regulator protein (CFTR) gene, with F508del being the most common. During the last years, small-molecule therapy chosen to contrast CF relied on compounds that correct CFTR misfolding and ER retention (correctors such as VX-809), or defective channel gating (potentiators such as VX-770). Combination therapy with the two series of drugs has been applied, leading to the approval of several multi-drugs such as Orkambi. Despite this, this treatment proved to be only partially effective making the search for novel modulators an urgent need to contrast CF. Recently, we reported compound 2a as reference compound of a series of aminoarylthiazole-VX-809 hybrid derivatives exhibiting promising F508del-CFTR corrector ability. Herein, we report exploring the docking mode of the prototype VX-809 and of 2a in order to derive useful guidelines for the rational design of novel optimized analogues. To demonstrate experimentally their effective F508del-CFTR-binding and rescuing potential, the most promising derivatives had been synthesized and evaluated in biological assays including YFP functional assay on F508del-CFTR CFBE41o-cells, trans epithelial electrical resistance (TEER) and surface plasmon resonance (SPR). This multidisciplinary strategy led to the discovery of a second series of hybrids including 7j and 7m endowed with higher potency than the prototype.

  DOI：

  10.1016/j.ejmech.2020.112833
• 作为产物：
  描述：

  1-(3-丙氧基苯基)乙酮 在 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 反应 6.0h， 生成 1-bromo-3'-propoxyacetophenone
  参考文献：
  名称：

  Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides

  摘要：

  Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides. Compounds 2 and 3 produced reductions of ca. 40% 2 h after doses of 100 mg/kg po. Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion. Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.

  DOI：

  10.1021/jm00130a013

文献信息

• Method for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes which are used in asymmetric reduction reactions
  申请人：Burgos Alain

  公开号：US20070055068A1

  公开（公告）日：2007-03-08

  A process for the in situ preparation of chiral compounds derived from oxazaborolidine-borane complexes, wherein a metal borohydride, a Lewis base and an inorganic acid ester are brought together and an optically active amino alcohol and optionally a halide are then added. The compound obtained is a complex that is useful as a catalyst in asymmetric reduction reactions. The reaction is performed by adding the substance to be reduced, particularly prochiral ketones or ether oximes, in order to synthesize chiral alcohols or chiral amines.

  一种用于原位制备从氧杂硼烷硼酸盐复合物中衍生的手性化合物的方法，其中将金属硼氢化物、路易斯碱和无机酸酯混合，然后加入手性活性氨基醇和可选的卤化物。所得化合物是一种复合物，可用作不对称还原反应中的催化剂。通过将待还原物质，特别是原始手性酮或醚肟加入以合成手性醇或手性胺来执行反应。
• Process for producing optically active carbinols
  申请人：SUMIKA FINE CHEMICALS Company, Limited

  公开号：EP0713848A1

  公开（公告）日：1996-05-29

  The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting with an unsymmetric ketone, an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid.

  本发明涉及一种生产光学活性的式(1)卤代甲基苯基甲醇的工艺，包括使用从硼烷和光学活性的式(3)α-苯基取代-β-氨基醇或光学活性的式(4)α-非取代-β-氨基醇中得到的不对称还原剂还原式(2)卤代甲基苯基酮。 本发明还涉及一种生产光学活性烷醇的工艺，包括与不对称酮、从式（5）光学活性β-氨基醇中得到的不对称还原剂、金属硼氢化物和路易斯酸或低级二烷基硫酸反应。
• Processes for preparing optically active alcohols and optically active amines
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0736509A2

  公开（公告）日：1996-10-09

  A process for preparing an optically active alcohol by reacting a prochiral ketone corresponding to the optically active alcohol and an acid with a mixture of (1) a boron-containing compound selected from the group consisting of i) a borane compound which is obtained from an optically active β-aminoalcohol and a boron hydride; or obtained from the optically active β-aminoalcohol, a metal borohydride and an acid and ii) an optically active oxazaborolidine and (2) a metal borohydride; and a process for preparing an optically active amine by reacting an oxime derivative and an acid with a mixture of (1) a boron-containing compound selected from the group consisting of i) a borane compound which is obtained from an optically active β-aminoalcohol and a boron hydride, or obtained from said optically active β-aminoalcohol, a metal borohydride and an acid and ii) an optically active oxazaborolidine, and (2) a metal borohydride.

  一种制备光学活性醇的工艺，其方法是将对应于光学活性醇的手性酮和酸与(1)选自以下组别的含硼化合物和(2)选自以下组别的含硼化合物的混合物反应：①从光学活性β-氨基醇和氢化硼中得到的硼烷化合物；或从光学活性β-氨基醇、金属硼氢化物和酸中得到的硼烷化合物；②光学活性噁唑硼烷和(2)金属硼氢化物；以及一种制备光学活性胺的工艺，其方法是使肟衍生物和酸与(1)一种含硼化合物与(2)一种金属硼氢化物的混合物反应，该含硼化合物选自以下组别：(1)一种硼烷化合物，该硼烷化合物由光学活性β-氨基醇和硼氢化物得到，或由所述光学活性β-氨基醇、金属硼氢化物和酸得到；以及(2)一种光学活性噁唑硼烷和(2)一种金属硼氢化物。
• Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides
  作者：Samuel J. Dominianni、Terence T. Yen

  DOI：10.1021/jm00130a013

  日期：1989.10

  Blood glucose levels in viable, yellow, obese, diabetic mice are reduced following oral administration of phenacylimidazolium halides. Compounds 2 and 3 produced reductions of ca. 40% 2 h after doses of 100 mg/kg po. Since these mice do not respond to sulfonylureas, the glucose-lowering activity of phenacylimidazolium salts in this model suggests a mechanism other than that of stimulating insulin secretion. Only phenacylimidazolium halides with electron-donating groups were active; other azolium salts or variations in the phenacyl portion (alterations in the keto function; chain lengthening or extensive branching) produced inactive compounds.
• Ago-allosteric modulators of human glucagon-like peptide 2 receptor
  作者：Kazuto Yamazaki、Hiroki Terauchi、Daisuke Iida、Hironori Fukumoto、Shuichi Suzuki、Takaki Kagaya、Mika Aoki、Koichiro Koyama、Takashi Seiki、Kazuma Takase、Misako Watanabe、Tohru Arai、Kappei Tsukahara、Junichi Nagakawa

  DOI：10.1016/j.bmcl.2012.08.026

  日期：2012.10

  Glucagon-like peptide 2 (GLP-2) is an intestinotropic peptide that binds to GLP-2 receptor (GLP-2R), a class-B G protein-coupled receptor (GPCR). Few synthetic agonists have been reported so far for class-B GPCRs. Here, we report the first scaffold compounds of ago-allosteric modulators for human GLP-2R, derived from methyl 2-[(2Z)-2-(2,5-dichlorothiophen-3-yl)-2-(hydroxyimino) ethyl] sulfanyl}benzoate (compound 1). (C) 2012 Elsevier Ltd. All rights reserved.